A Single Dose of Armodafinil Significantly Promotes Vigilance 11 Hours Post-Dose
Authors: Phillips, Jeffrey B.; Simmons, Rita G.; Arnold, Richard D.
Source: Military Medicine, Volume 176, Number 7, July 2011 , pp. 833-839(7)
Objective: This study was conducted to test the ability of armodafinil to promote vigilance among air traffic control operators 8 to 11 hours post-dose. Methods: Forty-eight U.S. Naval air traffic control students were assigned to one of two groups, 150 mg dose of armodafinil or placebo. At 8:00 a.m., participants were administered armodafinil or a placebo, after which they completed a standard work day. Participants returned at 3:45 p.m. to complete the 4-hour performance portion of the study, where they performed the psychomotor vigilance task. Results: The analysis showed a significant difference in vigilance between the armodafinil group and placebo (p < 0.05). Psychomotor vigilance task data revealed that participants receiving a 150 mg dose of armodafinil experienced significantly fewer lapses of attention compared to the control group. Conclusions: These results justify additional investigation into the efficacy of armodafinil to promote sustained vigilance in military operational settings where fatigue-related performance decrements are especially problematic.
Document Type: Research Article
Publication date: July 2011
- Military Medicine will be available on another platform. See: http://publications.amsus.org. Please contact the publisher at firstname.lastname@example.org for information on how to continue access to this title.
Military Medicine is the Association's official monthly journal. The objective of the Journal is to promote awareness of Federal medicine by providing a forum for responsible discussion of common ideas and problems relevant to Federal healthcare. Its mission is: To increase healthcare education by providing scientific and other information to its readers; to facilitate communication; and to offer a prestige publication for members' writings.
Military Medicine's 5-year Impact Factor: 1.061
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- Terms & Conditions
- Reviewer Information
- ingentaconnect is not responsible for the content or availability of external websites